FOLH1 and neoplasm: There was a clear trend of enhanced tumor growth inhibitionand increased survival after application of161Tb-PSMA-617 as compared to177Lu-PSMA-617 at all activity levels (Supplementary material, Fig. S4/S5,Table S8).